← Back to Clinical Trials
Recruiting NCT05772091

Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach

Trial Parameters

Condition Transthyretin Cardiac Amyloidosis
Sponsor Pr. Nicolas GIRERD
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-09-29
Completion 2024-03-31

Brief Summary

Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.

Eligibility Criteria

Inclusion Criteria: * Patients with suspicion of transthyretin cardiac amyloidosis * Age ≥18 years Exclusion Criteria: * Lack of data to confirm or overturn the transthyretin amyloidosis diagnostic * Echocardiographic data not allowing deep analysis (technical default, bad echogenicity of the patient) * Final diagnostic of AL or AA amyloidosis

Related Trials